Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
9007-12-9
Molecular formula
C151H226N40O45S3
Molecular weight
3417.9 g/mol
Drug class
Peptide hormonecalcitonin receptor agonist and inhibitor of osteoclastic bone resorption
Mechanism of action
Binds calcitonin receptors on osteoclasts, reducing osteoclast activity and bone resorption. It also has effects on renal calcium and phosphate handling; clinical use depends on formulation and jurisdiction.
Indications / reported uses
Short-term treatment of hypercalcaemia when other measures are inadequate
Treatment of Paget disease of bone in selected patients when alternative therapies are unsuitable
Selected osteoporosis indications in some jurisdictions; long-term use is restricted or discouraged in certain products because of safety concerns
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Calcitonin Environmental Risk Assessment (ERA) (the Calcitonin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.